Table 6.
Results of scenario analysis including exemestane and palbociclib + letrozole
| Total discounted costs (£) | Total discounted QALYs | Incremental costs (£) | Incremental QALYs | ICER (£/QALY) | |
|---|---|---|---|---|---|
| Fulvestrant | 49,523.48 | 3.23 | |||
| Anastrozole | 30,484.59 | 2.68 | 19,038.88 | 0.56 | 34,189.91 |
| Letrozole | 26,206.13 | 2.46 | 23,317.34 | 0.77 | 30,138.59 |
| Tamoxifen | 32,317.52 | 2.47 | 17,205.96 | 0.76 | 22,492.06 |
| Exemestane | 28,291.37 | 2.37 | 21,232.10 | 0.87 | 24,470.03 |
| Palbociclib + letrozole | 169,332.18 | 3.08 | − 119,808.71 | 0.15 | Fulvestrant dominant |
Costs are in 2016 British pounds sterling
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year